Low-Risk MDS (Myelodysplastic Syndromes) Omaha Patient and Family Hybrid Conference 2023
Dr. Vijaya Bhatt discusses Low-Risk MDS in accessible terminology during this session from the 2023 Omaha, NE, Patient and Family Hybrid Conference.
treatment
Afaf Osman, MD
Osman, Afaf
Hematologist/Oncologist
Huntsman Cancer Center, University of Utah
Online Profile:
Sagar S. Patel, MD
Patel, Sagar
Assistant Professor, Huntsman Cancer Institute
Huntsman Cancer Institute
Online Profile:
Alex Nester, MD
Nester, Alex
Assistant Professor, Division of Oncology & Hematology
University of Nebraska Medical Center
High Risk MDS Non-Transplant Therapies Current Therapies and Clinical Trials Omaha Patient and Family Hybrid Conference 2023
High Risk MDS Non-Transplant Therapies Current Therapies and Clinical Trials with Dr. Prajwal Dhakal
Aplastic Anemia Non-Transplant Therapies and Clinical Trials, from Omaha Patient and Family Hybrid Conference 2023
Amanda Przespolewski, DO
Amanda, Przespolewski
Assistant Professor, Medical Oncology
Roswell Park Comprehensive Cancer Center
Online Profile:
ASH 2022 Update: Aplastic Anemia and PNH
Srinivas Tantravahi, MBBS, MRCP
Srinivas, Tantravahi
Hematologist
Huntsman Cancer Hospital
Dr. Tantravahi has received his medical degree from Guntur medical college, India. He then completed Internal Medicine residency and Hematology and Oncology fellowship training at University of Utah Hospital. His clinical interests include multiple myeloma, stem cell transplantation, and myeloproliferative neoplasm. Research interests are targeted therapy in CML and myeloproliferative neoplasms.
Online Profile:
2023 Omaha Patient and Family Hybrid Conference
Here are the session recordings and the presentations for the 2023 Omaha Patient and Family Hybrid Conference.
Event Date:
Sat, 04/15/2023 - 9:30am (EDT)
Conference Materials:
Bone Marrow Disease(s):
Conference Event Type: